1. a history of serious allergy to any vaccine in the past, or a history of serious allergy to any component of the studied vaccine, including aluminum preparations, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, angioneurotic edema, allergic constitution (such as allergic to two or more drugs, food or pollen); 2. confirmed cases of novel coronavirus infection, asymptomatic infections or positive history of novel coronavirus nucleic acid testing; 3. patients with uncontrollable lymphoproliferative disease, aplastic anemia, primary immune thrombocytopenia (itp), and haemorrhagic disease; 4. a history of congenital or acquired immunodeficiency or autoimmune diseases; 5. the life expectancy of patients with malignant tumors is less than 1 year; 6. patients with uncontrolled epilepsy and other progressive nervous system diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); 7. patients with acute disease, or acute attack period of chronic disease, or uncontrolled severe chronic disease, such as hypertension beyond the control of drugs (systolic blood pressure ≥ 150 mmhg and/or diastolic blood pressure ≥ 100 mmhg); 8. those who have received inactivated vaccine within one week or attenuated vaccine within four weeks before vaccination; 9. subjects who have participated in other clinical studies or are participating in other clinical studies within 3 months; 10. the investigator believes that the subject has any disease or condition that may put the subject at risk, that the subject cannot complete the study as required by the protocol, and that there are conditions that interfere with the evaluation of vaccine response.

1. a history of serious allergy to any vaccine in the past, or a history of serious allergy to any component of the studied vaccine, including aluminum preparations, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, angioneurotic edema, allergic constitution (such as allergic to two or more drugs, food or pollen); 2. confirmed cases of novel coronavirus infection, asymptomatic infections or positive history of novel coronavirus nucleic acid testing; 3. patients with uncontrollable lymphoproliferative disease, aplastic anemia, primary immune thrombocytopenia (itp), and haemorrhagic disease; 4. a history of congenital or acquired immunodeficiency or autoimmune diseases; 5. the life expectancy of patients with malignant tumors is less than 1 year; 6. patients with uncontrolled epilepsy and other progressive nervous system diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); 7. patients with acute disease, or acute attack period of chronic disease, or uncontrolled severe chronic disease, such as hypertension beyond the control of drugs (systolic blood pressure ≥ 150 mmhg and/or diastolic blood pressure ≥ 100 mmhg); 8. those who have received inactivated vaccine within one week or attenuated vaccine within four weeks before vaccination; 9. subjects who have participated in other clinical studies or are participating in other clinical studies within 3 months; 10. the investigator believes that the subject has any disease or condition that may put the subject at risk, that the subject cannot complete the study as required by the protocol, and that there are conditions that interfere with the evaluation of vaccine response.

a history of serious allergy to any vaccine in the past, or a history of serious allergy to any component of the studied vaccine, including aluminum preparations, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, angioneurotic edema, allergic constitution (such as allergic to two or more drugs, food or pollen); confirmed cases of novel coronavirus infection, asymptomatic infections or positive history of novel coronavirus nucleic acid testing; patients with uncontrollable lymphoproliferative disease, aplastic anemia, primary immune thrombocytopenia (itp), and haemorrhagic disease; a history of congenital or acquired immunodeficiency or autoimmune diseases; the life expectancy of patients with malignant tumors is less than 1 year; patients with uncontrolled epilepsy and other progressive nervous system diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); patients with acute disease, or acute attack period of chronic disease, or uncontrolled severe chronic disease, such as hypertension beyond the control of drugs (systolic blood pressure ≥ 150 mmhg and/or diastolic blood pressure ≥ 100 mmhg); those who have received inactivated vaccine within one week or attenuated vaccine within four weeks before vaccination; subjects who have participated in other clinical studies or are participating in other clinical studies within 3 months; the investigator believes that the subject has any disease or condition that may put the subject at risk, that the subject cannot complete the study as required by the protocol, and that there are conditions that interfere with the evaluation of vaccine response.

a history of serious allergy to any vaccine in the past, or a history of serious allergy to any component of the studied vaccine, including aluminum preparations, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, angioneurotic edema, allergic constitution (such as allergic to two or more drugs, food or pollen); confirmed cases of novel coronavirus infection, asymptomatic infections or positive history of novel coronavirus nucleic acid testing; patients with uncontrollable lymphoproliferative disease, aplastic anemia, primary immune thrombocytopenia (itp), and haemorrhagic disease; a history of congenital or acquired immunodeficiency or autoimmune diseases; the life expectancy of patients with malignant tumors is less than 1 year; patients with uncontrolled epilepsy and other progressive nervous system diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); patients with acute disease, or acute attack period of chronic disease, or uncontrolled severe chronic disease, such as hypertension beyond the control of drugs (systolic blood pressure ≥ 150 mmhg and/or diastolic blood pressure ≥ 100 mmhg); those who have received inactivated vaccine within one week or attenuated vaccine within four weeks before vaccination; subjects who have participated in other clinical studies or are participating in other clinical studies within 3 months; the investigator believes that the subject has any disease or condition that may put the subject at risk, that the subject cannot complete the study as required by the protocol, and that there are conditions that interfere with the evaluation of vaccine response.